galcanezumab

Attention Biotech Investors: Mark Your Calendar For These September PDUFA Dates
Attention Biotech Investors: Mark Your Calendar For These September PDUFA Dates
Yahoo/Benzinga
biotech
FDA
Roche
Tecentriq
GSK
mepolizumab
Teva Pharmaceutical
fremanezumab
Adamis Pharmaceuticals
Symjepi
Insmed
ALIS
Antares
XYOSTED
Eli Lilly
galcanezumab
Pfizer
dacomitinib
Flag link:
Lilly's CGRP drug succeeds in 'worst kind of migraine'
Lilly's CGRP drug succeeds in 'worst kind of migraine'
Biopharma Dive
Eli Lilly
cluster headaches
migraines
galcanezumab
Flag link:
Lilly's bet on pain stands out amid bare pharma pipeline
Lilly's bet on pain stands out amid bare pharma pipeline
Biopharma Dive
Eli Lilly
painkillers
galcanezumab
tanezumab
Lasmiditan
Flag link:
Eli Lilly says late-stage, 12-month study showed its migraine treatment was safe, effective
Eli Lilly says late-stage, 12-month study showed its migraine treatment was safe, effective
Marketwatch
Eli Lilly
migraines
clinical trials
galcanezumab
Flag link:
Eli Lilly posts promising PhIII migraine results, but settles into the pack in the last leg of the race to the FDA
Eli Lilly posts promising PhIII migraine results, but settles into the pack in the last leg of the race to the FDA
Endpoints
Eli Lilly
migraines
galcanezumab
Flag link:
Lilly preps galcanezumab for 2017 filing
Lilly preps galcanezumab for 2017 filing
BioPharma Dive
Eli Lilly
galcanezumab
migraines
FDA
Flag link:
Playing catch-up, Eli Lilly is hustling positive PhIII CGRP migraine data to the FDA as late-stage rivalry heats up
Playing catch-up, Eli Lilly is hustling positive PhIII CGRP migraine data to the FDA as late-stage rivalry heats up
Endpoints
Eli Lilly
migraines
galcanezumab
Flag link:
Portola Approval And Headache Data From Lilly
Portola Approval And Headache Data From Lilly
Seeking Alpha
Portola Pharmaceuticals
Eli Lilly
andexanet alfa
galcanezumab
Flag link: